Eddie Rashan

Biochemist. Postdoc @mvh_lab @KochInstitute | he/him | BlueSky: @edreesrashan.bsky.social

[Eddie Rashan @EdreesRashan]

As promised, a 🧵 on our recent article now out in @NatureSMB! Co-led with @AbbyBartlett_ @Pagliarini_Lab @JudithSimcox, we find ACAD10/11 are NOT like other acyl-CoA dehydrogenases and instead catabolize atypical lipids called 4-hydroxy acids 🤯#lipidtime https://t.co/u1E4kniIso

[Eddie Rashan @EdreesRashan]

@rahulg603 @Nature Amazing work, Rahul. Congratulations!

[Rahul Gupta @rahulg603]

We took ~750,000 whole genomes and found the putative mechanism by which mitochondrial DNA mutations accumulate with age in blood. Spoiler: we think these mutations arise by replication error and tag age-related clonal hematopoiesis. Read @Nature https://t.co/Xlc0yIDgG1

[Kelsey Fisher-Wellman, PhD @KFW_Lab]

Collaboration between our group and the Tirosh lab exploring a novel mTOR activator (they devloped) in combination with ixazomib for treatment of Acute Myeloid Leukemia! - https://t.co/aiEsTvYEjY

[Brett Chrest @Chrest_brett]

📢NEW REVIEW: We introduce the distinction between essentiality and disproportionate essentiality when targeting OxPhos in cancer, and explain why this target does not support a therapeutic window once we consider the rest of the organism.
https://t.co/75Cl8ezvP5

[Farooqi Lab @Farooqi_Lab]

In a paper just published in @sciencemagazine, we teamed up with @teichlab to construct the most detailed atlas to date of hormone production and action in humans at cellular resolution. (1/8)

Link: https://t.co/5iPOCq9yfu

[Cell Metabolism @Cell_Metabolism]

New! Online now: Iron-addicted colorectal cancers exploit heme-complex II axis to resist oxidative cell death https://t.co/NyFHQMhsAM

[Matthias Mann Lab @labs_mann]

1/5
Cell identity is written in the proteome, not in the DNA, and not always in the RNA. Out on bioRxiv today: The first cell type-resolved, MS-based proteomic atlas of the human body.
https://t.co/5RJ0nVoQ81

[Vamsi Mootha @VamsiMootha]

Delighted to share the final version of our story on mtDNA mutations and aging, published today.

We show mtDNA mutation burden is a sensitive marker of somatic mosaicism (due to CHIP) in blood.

Curious if this pattern will extens to solid organs, too.

https://t.co/GcFKwwpfUu

[Gary Siuzdak @kadzuis]

METLIN 960K is now integrated into the Mass Analytica MARS platform.

Empirical MS/MS spectra from ~960,000 authentic standards.

Not predicted. Not crowdsourced.

Experimental data at scale.

https://t.co/LNPMX8Reu7

#Metabolomics #METLIN

Publication: https://t.co/VHryTkoyHD

[Patrick Hsu @pdhsu]

@editasmed is also doing very exciting preclinical work with EDIT-401 by deleting the 3' UTR of LDLR, leading to 6-fold upregulation of the LDL receptor. They get 90% reduction of LDL-C, LPa, and ApoB in monkeys - the three major atherogenic lipoproteins

VERVE-102 only gets 62% reduction of LDL-C...but of course this is human data. Editas IR says they will have first-in-human POC of their program by end of 2026. Stay tuned!

[Eric Topol @EricTopol]

Just published @NEJM
Marked and durable reduction of LDL cholesterol with one shot PCSK9 gene base editing @skathire https://t.co/3fU9EjatjH

[Satoshi Koyama @skoyamamd]

Excited to share our new publication: "Exome-wide association study for blood lipids in 1,158,017 individuals from diverse populations." https://t.co/PUac0Og1Tx

This study explores how multi-ancestry DNA sequencing has identified rare coding variants that influence blood lipids and atherosclerotic risk.

Highlights include:
• Discovery of rare coding variants across more than 1 million participants
• Identification of novel lipid-associated genes
• Insights into variant annotation and recessive associations
• Potential therapeutic targets for coronary artery disease
• The power of global biobank collaboration

I extend my gratitude to all collaborators, participants, and consortium teams who made this research possible. I am proud to be part of this effort. Special thanks to my mentors, Drs. Yan Sun, Peter Wilson, @patrick_ellinor, and @pnatarajanmd, for their guidance and support throughout this work!

For more details, see the previous thread:
https://t.co/GlTcSYfKDJ

[Emma J Chory @chorye]

This one is hard to see.

The NIH Early Independence Award, one of the most competitive grants in the country for young scientists, will not go forward in FY2026. NIH says this is due to “administrative changes to funding opportunity processing and delays in approvals.”

[Donita Brady of Brady Lab UPenn @bradylabupenn]

Excited to share our new @biorxivpreprint from the @BradyLab & @PaulTitchenell lab on MASH, phosphatidylcholine metabolism, and copper biology with @JaclynE_x8 &

https://t.co/dgPL06pLzx

[Sara Wahedi @SaraWahedi]

Please share!!:

If you know of any Afghan women/girls who were accepted to a university but couldn’t get a scholarship or find funding, please DM me.

We’re working on a few things to approach this.

[Max Marchione @maxmarchione]

Retatrutide phase 3 obesity trial just came out and the results are genuinely insane:

- 28.3% bodyweight lost on 12mg over 80 weeks
- 70.3 pounds on avg. or 31.9 kg
- 45.3% of patients hit 30%+ weight loss (this is bariatric surgery territory)
- 30.3% weight loss (85 lbs) at 104 weeks in higher-BMI patients
- 65.3% of 12mg patients dropped below the obesity BMI threshold
- 19% loss on 4mg over 80 weeks (47.2 lbs) with fewer dropouts than placebo (4.1% vs 4.9%)
- significant drops in blood pressure, triglycerides, non-HDL cholesterol, waist circumference, and hsCRP
- no cardiac or liver signals

Retatrutide is going to completely overshadow tirzepatide and semaglutide, and take the throne as the best-selling drug of all time.

[Eddie Rashan @EdreesRashan]

@NaOHBartfield You don't find the deafening screech soothing?

[Arpit Sharma, PhD @arpit_science]

Our paper just went live on @NatureAging. Peroxisomes are understudied & regarded as organelles with functions ancillary to those of the mitochondria. We shift this paradigm by demonstrating how peroxisomes actively guide organelles cascades & maintain them to drive healthy aging

[Bushra Ateeq @bushraiitk]

Happy to share our recent paper, in which we show that DKC1 is both a therapeutic target and a diagnostic biomarker in colorectal cancer. DKC1 is a critical part of the telomerase complex, and when elevated, it fuels cancer progression.
Link: https://t.co/ztOcPiMWmT

[Kelsey Fisher-Wellman, PhD @KFW_Lab]

New review from our group taking a critical look at OxPhos as a cancer target......and suggestions for where the field goes next. Published in @Biochem_Journal
https://t.co/rwU1AIymEK